Contracts › HHSN272201700082C
HHSN272201700082C: Igf::Ot::Igf Advanced Development of Multivalent Vaccine Candidates for Filovirus and Lassa Fever
Awarded to Thomas Jefferson University by National Institutes of Health (NIH).
$26.0Mobligated
$27.0Mpotential value
31 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HHSN272201700082C |
|---|---|
| Awardee | Thomas Jefferson University |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541712 Research and Development in the Physical, Engineering, and Life Sciences (Except Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | PA |
| Offers received | 5 |
| Period of performance | 31 August 2017 to 31 January 2027 |
| Potential end | 31 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541712 contracts · All expiring contracts · USASpending record